FDA is­sues new guid­ance on wet AMD drug de­vel­op­ment

FDA has new draft guid­ance for drug­mak­ers pur­su­ing wet AMD, an eye de­gen­er­a­tion dis­ease that caus­es a loss of vi­sion.

While drug­mak­ers aren’t re­quired to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.